Cargando…
Rethinking Antigen Source: Cancer Vaccines Based on Whole Tumor Cell/tissue Lysate or Whole Tumor Cell
Cancer immunotherapies have improved human health, and one among the important technologies for cancer immunotherapy is cancer vaccine. Antigens are the most important components in cancer vaccines. Generally, antigens in cancer vaccines can be divided into two categories: pre‐defined antigens and u...
Autores principales: | Diao, Lu, Liu, Mi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10401146/ https://www.ncbi.nlm.nih.gov/pubmed/37254712 http://dx.doi.org/10.1002/advs.202300121 |
Ejemplares similares
-
Enhanced in vivo anti-tumor efficacy of whole tumor lysate in combination with whole tumor cell-specific polyclonal antibody
por: Rahimmanesh, Ilnaz, et al.
Publicado: (2023) -
In vivo vaccination with cell line-derived whole tumor lysates: neoantigen quality, not quantity matters
por: Salewski, Inken, et al.
Publicado: (2020) -
Use of tumor cell lysate to develop peptide vaccine targeting cancer-testis antigens
por: Malhotra, Jyoti, et al.
Publicado: (2021) -
Dataset from a proteomics analysis of tumor antigens shared between an allogenic tumor cell lysate vaccine and pancreatic tumor tissue.
por: Stingl, C., et al.
Publicado: (2022) -
Whole Tumor Antigen Vaccines: Where Are We?
por: Chiang, Cheryl Lai-Lai, et al.
Publicado: (2015)